ResultsIQ

ResultsIQ › Latest results › Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited Q3 FY26 results deck summary

NSE: GUJTHEM · BSE: 506879

Results deck of 5 Feb 2026, summarised by AI from the filing.

Q3 FY26 revenue grew 10% to ₹43.4 cr, EBITDA grew 12.9% to ₹21.31 cr, PAT ₹12.5 cr; new fermentation facility completed.

Key takeaways

  1. Q3 FY26 revenue Revenue grew 10% year-on-year to ₹43.4 cr.
  2. EBITDA growth EBITDA grew 12.9% to ₹21.31 cr; PAT stood at ₹12.5 cr.
  3. New fermentation facility New fermentation facility completed; production of existing products underway.
  4. API validation Validation batches completed in API block; aim to forward-integrate into APIs.
  5. Hybrid power plant Setting up a hybrid power plant in Gujarat for captive consumption.

Original filing on BSE

Gujarat Themis Biosyn Limited Q1 FY27 results

As filed: Revenue ₹43.8 cr (+22% year on year), EBITDA ₹20.8 cr (+49% year on year), PAT ₹11.1 cr (+23% year on year), EBITDA margin 47.5% (+861 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹44.2 cr (+16% year on year), EBITDA ₹19.4 cr (+21% year on year), PAT ₹10.9 cr (−9% year on year), EBITDA margin 43.8% (+169 bps). Score 55 of 100, In line with trend. EBITDA margin rose 169 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: +8.8% in 30 days (Nifty 500: +2.1%).
  • Q3 FY26: Revenue ₹43.4 cr, EBITDA ₹21.3 cr, PAT ₹12.5 cr, EBITDA margin 49.1%. Not scored. No result for the same quarter last year. Share price after the results: −9.3% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹42.0 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 50.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.8% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹36.0 cr, EBITDA ₹14.0 cr, PAT ₹9.0 cr, EBITDA margin 38.9%. Not scored. No result for the same quarter last year. Share price after the results: −3.2% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹38.0 cr, EBITDA ₹16.0 cr, PAT ₹12.0 cr, EBITDA margin 42.1%. Not scored. No result for the same quarter last year. Share price after the results: −3.3% in 30 days (Nifty 500: +0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gujarat Themis Biosyn Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.